Search Medical Condition
Please enter condition
Please choose location from dropdown

Aichi, Nagoya, Japan Clinical Trials

A listing of Aichi, Nagoya, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (278) clinical trials

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

Phase

8.12 miles

Learn More »

An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

The purpose of this study is to evaluate the efficacy of SHP647 as maintenance therapy treatment of remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

Phase

8.12 miles

Learn More »

A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

The purpose of this study is to evaluate the safety and tolerability of long-term treatment with SHP647 in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD).

Phase

8.12 miles

Learn More »

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease

Phase

8.12 miles

Learn More »

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Phase

8.12 miles

Learn More »

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

Phase

8.12 miles

Learn More »

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

This is an investigational study, also known as LATTICE-CD, of the experimental medication BMS-986165 in participants with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

9.34 miles

Learn More »

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Patients who complete definitive treatment with SoC SBRT and are confirmed to meet all eligibility criteria will be randomized 1:1 to durvalumab or placebo. The primary objective of this study is to assess the efficacy of durvalumab monotherapy compared to placebo in terms of PFS. Key secondary is to assess ...

Phase

9.34 miles

Learn More »

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

The drug being tested in this study is called brigatinib (AP26113). Brigatinib is being tested to treat people who have anaplastic lymphoma kinase-positive (ALK+), advanced non-small-cell lung cancer (NSCLC). The study will enroll approximately 103 patients. Participants will be assigned to the treatment group: Brigatinib All participants will be asked ...

Phase

9.34 miles

Learn More »

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

Phase

9.43 miles

Learn More »